VA SB278

Directs the Secretary of Health and Human Resources to convene a stakeholder work group to evaluate the impacts of the federal 340B Drug Pricing Program in Virginia, focusing on governance, transparency, and pharmacy services in rural and underserved communities

Requires the work group to include representatives from healthcare associations, hospitals, pharmacists, Federally Qualified Health Centers, pharmaceutical manufacturers, health plans, and chain drug stores

Mandates review of the number and location of covered entities and contract pharmacies in the Commonwealth, along with their contractual arrangements including dispensing fees and financial practices

Directs evaluation of potential state-level transparency and governance requirements to prevent Medicaid patient diversion and duplicate discounts, and to ensure 340B revenue supports low-income and underserved individuals

Requires the Secretary to submit findings and recommendations to relevant Senate and House committees by November 1, 2026